Novacap announces the signature of an agreement to acquire PCI Synthesis
Novacap expands its pharmaceutical offering in the US with PCI synthesis acquisition
PCI Synthesis is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, MA. It is the largest small molecule drug substance manufacturer in New England area.
PCI Synthesis is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other chemical products for the medical device industry. As a CDMO, PCI Synthesis provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules.